Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHIELD DMD: Satralizumab in Pediatric Duchenne Muscular Dystrophy
NCT06450639Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Apr 2025
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of satralizumab in Duchenne muscular dystrophy (DMD), sponsored by Roche. Primary endpoint: Lumbar Spine Bone Mineral Density Z-score at 24 weeks. Started Apr 2025; status: active, not recruiting.
02
Drugs
satralizumab
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT06450639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06450639.